Long-term valbenazine safety study for chorea in Huntington disease
Tests long-term safety of valbenazine in adults with Huntington disease movements.
Plain-language title generated from the registry record
Registry title: Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada
Key facts
- Where
- Ottawa, Toronto, and Vancouver, CanadaSee the 3 sites
- Phase
- Phase 3
Where in Canada
- OttawaOttawa, CanadaNo longer taking part
- TorontoToronto, CanadaNo longer taking part
- VancouverVancouver, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Neurocrine Biosciences
- Trial code
- NCT06312189
- Record updated
- 18 June 2026
- Original description
This study will evaluate long-term safety and tolerability of valbenazine in participants with chorea associated with Huntington Disease (HD) who participated in Study NBI-98854-HD3006 (NCT04400331) in Canada.Read full original descriptionShow less
Open-Label Study of Valbenazine for the Treatment of Chorea Associated With Huntington Disease in Canada
This study will evaluate long-term safety and tolerability of valbenazine in participants with chorea associated with Huntington Disease (HD) who participated in Study NBI-98854-HD3006 (NCT04400331) in Canada.
Inclusion: Participated in Study NBI-98854-HD3006 and completing dosing through the Week 156 visit; or were actively participating, receiving study treatment, and completed an early termination visit Study NBI-98854-HD3006 at the time of the study closure at sites in Canada; Participants of childbearing potential must agree to use contraception consistently while participating in the study until 30 days after last dose of the study treatment.
Exclusion: Have a medically significant abnormality, physical examination finding, clinically significant laboratory abnormality; Have difficulty swallowing; Are currently pregnant or breastfeeding.